Nucleus Capital
Nucleus Capital is a Berlin-based first-check deep-tech venture firm founded in 2020 by Isabella Fandrych and Maximilian Schwarz, investing at pre-seed and seed stage in programmable biology (synbio and techbio), food technology and neo-industrials across Europe and the US. Backed by KfW Capital, the European Investment Fund and Rentenbank, it runs a concentrated, thesis-driven portfolio of scientifically-led founders tackling human and planetary health. The firm operates its legal entity as Nucleus Capital Fund Management GmbH and recorded its first exit when portfolio company Officinae Bio was acquired by Maravai LifeSciences in 2025.
Key facts
Recent exits
Coverage notes
2 funds tracked, 23 portfolio companies (22 active · 1 realized). Verified weekly from public filings and deal announcements.
Sector breakdown
23 companiesFunds & portfolio
Every fund Nucleus Capital has raised, with its portfolio companies. Hand-checked from public filings.
Nucleus Capital IIVC2024 · 2yr€40M8 active
Unrealized
8 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Deep Tech |  UK | 2024 | |
| Energy |  US | 2025 | |
| Biotech | UK | 2026 | |
| Biotech | US | 2024 | |
| Biotech | US | 2025 | |
| ClimateTech |  Germany | 2025 | |
| Energy | Germany | 2025 | |
| Biotech |  Netherlands | 2026 |
UK· Entry 2024US· Entry 2025UK· Entry 2026US· Entry 2024US· Entry 2025Germany· Entry 2025Germany· Entry 2025Netherlands· Entry 2026Nucleus Capital IVC2021 · 5yr€7M14 active · 1 realized
Unrealized
14 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Software | Germany | 2023 | |
| Biotech | UK | 2023 | |
| Biotech |  Denmark | 2023 | |
| Energy | Netherlands | 2023 | |
| Biotech | UK | 2022 | |
| Industrials | US | 2023 | |
| Biotech | Netherlands | 2023 | |
| Consumer | US | 2021 | |
| FoodTech | Slovenia | 2021 | |
| Consumer | Germany | 2021 | |
| Biotech | UK | 2022 | |
| Business Services | Germany | 2022 | |
| Business Services | Netherlands | 2022 | |
| Biotech | Germany | 2021 |
Germany· Entry 2023UK· Entry 2023Denmark· Entry 2023Netherlands· Entry 2023UK· Entry 2022US· Entry 2023Netherlands· Entry 2023US· Entry 2021Germany· Entry 2021UK· Entry 2022Germany· Entry 2022Netherlands· Entry 2022Germany· Entry 2021Realized
1 exit| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Biotech |  Italy | 2021 | 2025 | Trade Sale | – |
Saved GPs appear in your watchlist, one click from your workspace.
Investment team
Senior partners. Hand-checked from public filings and the firm's own site.
Similar firms
Other private equity firms tracked on GP Intel.
Germany·€46M
Germany·€46M
Germany·€45M
Germany·€50M
Germany·€50M
Germany·€55M
Germany·€39M
Germany·€38M
Germany·€60M
Germany·€30M
Germany·€28M
Germany·€20MGet the full picture on Nucleus Capital.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Already a member? Sign in